

Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6214, MSC 7804, Bethesda, MD 20892, (301) 408-9512, [gubanics@csr.nih.gov](mailto:gubanics@csr.nih.gov).

*Name of Committee:* Risk, Prevention and Health Behavior Integrated Review Group; Psychosocial Development, Risk and Prevention Study Section.

*Date:* February 1–2, 2018.

*Time:* 8:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hyatt Arlington, 1325 Wilson Boulevard, Arlington, VA 22209.

*Contact Person:* Anna L. Riley, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3114, MSC 7759, Bethesda, MD 20892, 301-435-2889, [rileyann@csr.nih.gov](mailto:rileyann@csr.nih.gov).

*Name of Committee:* Bioengineering Sciences & Technologies Integrated Review Group; Biomaterials and Biointerfaces Study Section.

*Date:* February 1–2, 2018.

*Time:* 8:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Residence Inn Capital View, 2850 South Potomac Avenue, Arlington, VA 22202.

*Contact Person:* Joseph D. Mosca, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5158, MSC 7808, Bethesda, MD 20892, (301) 408-9465, [moscajos@csr.nih.gov](mailto:moscajos@csr.nih.gov).

*Name of Committee:* Population Sciences and Epidemiology Integrated Review Group; Kidney, Nutrition, Obesity and Diabetes Study Section.

*Date:* February 1–2, 2018.

*Time:* 8:30 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Marriott Wardman Park Washington DC Hotel, 2660 Woodley Road NW, Washington, DC 20008.

*Contact Person:* Fungai Chanetsa, MPH, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3135, MSC 7770, Bethesda, MD 20892, 301-408-9436, [fungai.chanetsa@nih.hhs.gov](mailto:fungai.chanetsa@nih.hhs.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: December 26, 2017.

**Natasha M. Copeland,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2017-28226 Filed 12-29-17; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Substance Abuse and Mental Health Services Administration

#### Current List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies

**AGENCY:** Substance Abuse and Mental Health Services Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Department of Health and Human Services (HHS) notifies federal agencies of the laboratories and Instrumented Initial Testing Facilities (IITF) currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines).

A notice listing all currently HHS-certified laboratories and IITFs is published in the **Federal Register** during the first week of each month. If any laboratory or IITF certification is suspended or revoked, the laboratory or IITF will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines.

If any laboratory or IITF has withdrawn from the HHS National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end and will be omitted from the monthly listing thereafter.

This notice is also available on the internet at <http://www.samhsa.gov/workplace>.

#### FOR FURTHER INFORMATION CONTACT:

Giselle Hersh, Division of Workplace Programs, SAMHSA/CSAP, 5600 Fishers Lane, Room 16N03A, Rockville, Maryland 20857; 240-276-2600 (voice).

**SUPPLEMENTARY INFORMATION:** The Department of Health and Human Services (HHS) notifies federal agencies of the laboratories and Instrumented Initial Testing Facilities (IITF) currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory Guidelines were first published in the **Federal Register** on April 11, 1988 (53 FR 11970), and subsequently revised in the **Federal Register** on June 9, 1994 (59 FR 29908); September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 19644); November 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); April 30, 2010 (75 FR 22809); and on January 23, 2017 (82 FR 7920).

The Mandatory Guidelines were initially developed in accordance with

Executive Order 12564 and section 503 of Public Law 100-71. The “Mandatory Guidelines for Federal Workplace Drug Testing Programs,” as amended in the revisions listed above, requires strict standards that laboratories and IITFs must meet in order to conduct drug and specimen validity tests on urine specimens for federal agencies.

To become certified, an applicant laboratory or IITF must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification, a laboratory or IITF must participate in a quarterly performance testing program plus undergo periodic, on-site inspections.

Laboratories and IITFs in the applicant stage of certification are not to be considered as meeting the minimum requirements described in the HHS Mandatory Guidelines. A HHS-certified laboratory or IITF must have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA), which attests that it has met minimum standards.

In accordance with the Mandatory Guidelines dated January 23, 2017 (82 FR 7920), the following HHS-certified laboratories and IITFs meet the minimum standards to conduct drug and specimen validity tests on urine specimens:

#### HHS-Certified Instrumented Initial Testing Facilities

Dynacare, 6628 50th Street NW, Edmonton, AB Canada T6B 2N7, 780-784-1190 (Formerly: Gamma-Dynacare Medical Laboratories)

#### HHS-Certified Laboratories

ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624, 844-486-9226

Alere Toxicology Services, 1111 Newton St., Gretna, LA 70053, 504-361-8989/800-433-3823 (Formerly: Kroll Laboratory Specialists, Inc., Laboratory Specialists, Inc.)

Alere Toxicology Services, 450 Southlake Blvd., Richmond, VA 23236, 804-378-9130 (Formerly: Kroll Laboratory Specialists, Inc., Scientific Testing Laboratories, Inc.; Kroll Scientific Testing Laboratories, Inc.)

Baptist Medical Center-Toxicology Laboratory, 11401 I-30, Little Rock, AR 72209-7056, 501-202-2783 (Formerly: Forensic Toxicology Laboratory Baptist Medical Center)

Clinical Reference Laboratory, Inc., 8433 Quivira Road, Lenexa, KS 66215-2802, 800-445-6917

DrugScan, Inc., 200 Precision Road, Suite 200, Horsham, PA 19044, 800-235-4890

Dynacare\*, 245 Pall Mall Street,  
London, ONT, Canada N6A 1P4, 519-  
679-1630 (Formerly: Gamma-  
Dynacare Medical Laboratories)  
ElSohly Laboratories, Inc., 5 Industrial  
Park Drive, Oxford, MS 38655, 662-  
236-2609  
Laboratory Corporation of America  
Holdings, 7207 N. Gessner Road,  
Houston, TX 77040, 713-856-8288/  
800-800-2387  
Laboratory Corporation of America  
Holdings, 69 First Ave., Raritan, NJ  
08869, 908-526-2400/800-437-4986  
(Formerly: Roche Biomedical  
Laboratories, Inc.)  
Laboratory Corporation of America  
Holdings, 1904 TW Alexander Drive,  
Research Triangle Park, NC 27709,  
919-572-6900/800-833-3984  
(Formerly: LabCorp Occupational  
Testing Services, Inc., CompuChem  
Laboratories, Inc.; CompuChem  
Laboratories, Inc., A Subsidiary of  
Roche Biomedical Laboratory; Roche  
CompuChem Laboratories, Inc., A  
Member of the Roche Group)  
Laboratory Corporation of America  
Holdings, 1120 Main Street,  
Southaven, MS 38671, 866-827-8042/  
800-233-6339 (Formerly: LabCorp  
Occupational Testing Services, Inc.;  
MedExpress/National Laboratory  
Center)  
LabOne, Inc. d/b/a Quest Diagnostics,  
10101 Renner Blvd., Lenexa, KS  
66219, 913-888-3927/800-873-8845  
(Formerly: Quest Diagnostics  
Incorporated; LabOne, Inc.; Center for  
Laboratory Services, a Division of  
LabOne, Inc.)  
MedTox Laboratories, Inc., 402 W.  
County Road D, St. Paul, MN 55112,  
651-636-7466/800-832-3244  
Legacy Laboratory Services—MetroLab,  
1225 NE 2nd Ave., Portland, OR  
97232, 503-413-5295/800-950-5295  
Minneapolis Veterans Affairs Medical  
Center, Forensic Toxicology  
Laboratory, 1 Veterans Drive,  
Minneapolis, MN 55417, 612-725-  
2088, Testing for Veterans Affairs  
(VA) Employees Only  
National Toxicology Laboratories, Inc.,  
1100 California Ave., Bakersfield, CA  
93304, 661-322-4250/800-350-3515  
One Source Toxicology Laboratory, Inc.,  
1213 Genoa-Red Bluff, Pasadena, TX  
77504, 888-747-3774 (Formerly:  
University of Texas Medical Branch,  
Clinical Chemistry Division; UTMB  
Pathology-Toxicology Laboratory)  
Pacific Toxicology Laboratories, 9348  
DeSoto Ave., Chatsworth, CA 91311,  
800-328-6942 (Formerly: Centinela  
Hospital Airport Toxicology  
Laboratory)  
Pathology Associates Medical  
Laboratories, 110 West Cliff Dr.,

Spokane, WA 99204, 509-755-8991/  
800-541-7891x7

Phamatech, Inc., 15175 Innovation  
Drive, San Diego, CA 92128, 888-  
635-5840

Quest Diagnostics Incorporated, 1777  
Montreal Circle, Tucker, GA 30084,  
800-729-6432 (Formerly: SmithKline  
Beecham Clinical Laboratories;  
SmithKline Bio-Science Laboratories)

Quest Diagnostics Incorporated, 400  
Egypt Road, Norristown, PA 19403,  
610-631-4600/877-642-2216  
(Formerly: SmithKline Beecham  
Clinical Laboratories; SmithKline Bio-  
Science Laboratories)

Quest Diagnostics Incorporated, 8401  
Fallbrook Ave., West Hills, CA 91304,  
818-737-6370 (Formerly: SmithKline  
Beecham Clinical Laboratories)

Redwood Toxicology Laboratory, 3700  
Westwind Blvd., Santa Rosa, CA  
95403, 800-255-2159

STERLING Reference Laboratories, 2617  
East L Street, Tacoma, Washington  
98421, 800-442-0438

US Army Forensic Toxicology Drug  
Testing Laboratory, 2490 Wilson St.,  
Fort George G. Meade, MD 20755-  
5235, 301-677-7085, Testing for  
Department of Defense (DoD)  
Employees Only

\* The Standards Council of Canada  
(SCC) voted to end its Laboratory  
Accreditation Program for Substance  
Abuse (LAPSA) effective May 12, 1998.  
Laboratories certified through that  
program were accredited to conduct  
forensic urine drug testing as required  
by U.S. Department of Transportation  
(DOT) regulations. As of that date, the  
certification of those accredited  
Canadian laboratories will continue  
under DOT authority. The responsibility  
for conducting quarterly performance  
testing plus periodic on-site inspections  
of those LAPSA-accredited laboratories  
was transferred to the U.S. HHS, with  
the HHS' NLCP contractor continuing to  
have an active role in the performance  
testing and laboratory inspection  
processes. Other Canadian laboratories  
wishing to be considered for the NLCP  
may apply directly to the NLCP  
contractor just as U.S. laboratories do.

Upon finding a Canadian laboratory to  
be qualified, HHS will recommend that  
DOT certify the laboratory (**Federal  
Register**, July 16, 1996) as meeting the  
minimum standards of the Mandatory  
Guidelines published in the **Federal  
Register** on January 23, 2017 (82 FR  
7920). After receiving DOT certification,  
the laboratory will be included in the  
monthly list of HHS-certified

laboratories and participate in the NLCP  
certification maintenance program.

**Charles LoDico**,  
*Chemist*.

[FR Doc. 2017-28249 Filed 12-29-17; 8:45 am]

**BILLING CODE 4160-20-P**

## DEPARTMENT OF HOMELAND SECURITY

### Federal Emergency Management Agency

[Docket ID FEMA-2017-0002]

#### Final Flood Hazard Determinations

**AGENCY:** Federal Emergency  
Management Agency, DHS.

**ACTION:** Notice.

**SUMMARY:** Flood hazard determinations,  
which may include additions or  
modifications of Base Flood Elevations  
(BFEs), base flood depths, Special Flood  
Hazard Area (SFHA) boundaries or zone  
designations, or regulatory floodways on  
the Flood Insurance Rate Maps (FIRMs)  
and where applicable, in the supporting  
Flood Insurance Study (FIS) reports  
have been made final for the  
communities listed in the table below.

The FIRM and FIS report are the basis  
of the floodplain management measures  
that a community is required either to  
adopt or to show evidence of having in  
effect in order to qualify or remain  
qualified for participation in the Federal  
Emergency Management Agency's  
(FEMA's) National Flood Insurance  
Program (NFIP). In addition, the FIRM  
and FIS report are used by insurance  
agents and others to calculate  
appropriate flood insurance premium  
rates for buildings and the contents of  
those buildings.

**DATES:** The date of May 15, 2018 has  
been established for the FIRM and,  
where applicable, the supporting FIS  
report showing the new or modified  
flood hazard information for each  
community.

**ADDRESSES:** The FIRM, and if  
applicable, the FIS report containing the  
final flood hazard information for each  
community is available for inspection at  
the respective Community Map  
Repository address listed in the tables  
below and will be available online  
through the FEMA Map Service Center  
at <https://msc.fema.gov> by the date  
indicated above.

**FOR FURTHER INFORMATION CONTACT:** Rick  
Sacbibit, Chief, Engineering Services  
Branch, Federal Insurance and  
Mitigation Administration, FEMA, 400  
C Street SW, Washington, DC 20472,